Survival benefit was explored across multiple types of cancer, including haematological malignancy, and subgroup analysis suggested that those with non-small cell lung cancer, melanoma, renal-cell carcinoma, and multiple myeloma gained benefit from anti-PD-1/PD-L1 inhibitors in terms of both OS and PFS. Here, CD274 is linked to melanoma.